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Abstract
Hereditary syndromes are responsible for 10 % of
gynaecologic cancers, among which hereditary breast-
ovarian cancer and hereditary non-polyposis colon cancer
syndromes, known as HBOC and Lynch syndromes re-
spectively, present the highest relative risk. The latter pre-
disposes to endometrial cancer and both contribute to
ovarian cancer. Cowden syndrome-related endometrial can-
cer and the increased risk of ovarian, uterine and cervical
cancers associated with Peutz-Jeghers syndrome, are also
demonstrated, while Li-Fraumeni syndrome patients are
prone to develop ovarian and endometrial cancers. Despite
these syndromes’ susceptibility to gynaecologic cancers
being consensual, it is still not clear whether these tu-
mours have any epidemiologic, clinical, pathologic or im-
aging specific features that could allow any of the inter-
vening physicians to raise suspicion of a hereditary syn-
drome in patients without known genetic risk. Moreover,
controversy exists regarding both screening and surveil-
lance schemes. Our literature review provides an updated
perspective on the evidence-based specific features of tu-
mours related to each of these syndromes as well as on
the most accepted screening and surveillance guidelines. In
addition, some illustrative cases are presented.
Teaching Points
• HBOC syndrome is mainly associated with ovarian HGSC,
which arises in fallopian fimbriae.
• LS-related endometrial tumours show histological diversity
and predilection for lower uterine segment.
• LS and CS-related ovarian cancers are mostly of non-serous
type, usually endometrioid.
•Ovarian SCTATand cervical adenomamalignum are strong-
ly associated with PJS.
•Unfortunately, hereditary gynaecologic cancers do not seem
to have distinctive imaging features.
Keywords Gynaecologic neoplasms . Hereditary cancer
syndromes . Neoplasms by histological type . Diagnostic
imaging . Practice guideline
Introduction
Recently, there have been significant advances in the knowl-
edge of female genital tract malignancies related to hereditary
cancer susceptibility syndromes. According to the American
Society of Clinical Oncology, hereditary syndromes are re-
sponsible for about 10 % of gynaecologic cancers [1].
One striking example is the discovery of the association
between germline mutations in breast cancer (BRCA) 1 and
2 genes and ovarian cancers in hereditary breast-ovarian can-
cer (HBOC) syndrome. Another one is the role of germline
mutations in DNAmismatch repair (MMR) genes in endome-
trial and ovarian carcinogenesis related to hereditary non-
polyposis colon cancer, also known as Lynch syndrome (LS).
Increased risk of endometrial cancer caused by mutation in
the phosphatase and tensin homolog (PTEN) gene in Cowden
syndrome (CS) is also demonstrated, as well as ovarian, uter-
ine and cervical cancers related to Peutz-Jeghers syndrome
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(PJS), due to liver kinase b1 (LKB1/STK11) gene mutation.
Ovarian and endometrial cancers also occur excessively in
patients with Li-Fraumeni syndrome (LFS), although the un-
derstanding of the contribution of this inherited germline mu-
tation in p53 is less established.
Despite the clear evidence of these inherited disorders’ sus-
ceptibility to gynaecologic cancers, it is still not generically
clear whether these tumours have any epidemiologic, clinical,
pathologic or imaging specific features that could allow any of
the intervening physicians to raise suspicion of a hereditary
syndrome in patients without known genetic risk. Moreover,
their screening and surveil lance schemes remain
controversial.
Our literature review provides an updated perspective on
the evidence-based specific features of tumours related to each
of these syndromes, as well as on the most accepted screening
and surveillance guidelines. In addition, some illustrative
cases are presented.
Hereditary breast-ovarian cancer syndrome
Ovarian cancer is the most lethal gynaecologic cancer, 70 %
being detected with advanced disease and therefore having
poor prognosis, with a 5-year survival rate of only 15 to
25 % for stage IV [2, 3].
90 % have epithelial origin [4], hereditary ones accounting
for at least 10% of cases [2, 5, 6] and the majority being due to
mutations in BRCA1 gene [5, 7]. Lifetime risk for ovarian
cancers is 40–66 % and 10–20 % in BRCA1 and BRCA2
germline mutation carriers, respectively [8–11], in contrast
to 1.8 % in the general population [12].
BRCA1 locus on chromosome 17q and BRCA2 on chro-
mosome 13q both function as tumour suppressor genes
[13–15]. These mutations, also associated with increased risk
of breast cancer, are both on the basis of HBOC and site-
specific ovarian cancer syndromes. Ethnic background signif-
icantly influences the mutation rates, which are particularly
high among Ashkenazi Jews compared to other populations
[16, 17].
Mean age of presentation of ovarian cancer in HBOC syn-
drome is 51–53 years, about 10 years earlier than in non-
BRCA mutations carriers [5, 12].
Concerning its pathology, the great majority are high-grade
serous carcinomas (HGSC) of papillary type, diagnosed at
advanced stage [2, 7, 12, 18]. Despite this, survival of ovarian
cancer seems to be surprisingly better in these women than in
sporadic ones [7], for unknown reasons.
Both cases of BRCA1mutation-related ovarian cancer pre-
sented (Figs. 1 and 2) were high-grade tumours with no tubal
involvement, diagnosed at younger ages than is typical for the
general population, which metastasized to lymph nodes. On
the other hand, a localized ovarian tumour in a BRCA2 mu-
tation carrier is presented in Fig. 3.
A curious detail regarding the origin of most ovarian
HGSC in patients with HBOC, suggested by recent studies
of prophylactically removed ovaries, is that instead of arising
primarily from the ovary as originally assumed, these tumours
actually seem to arise from the fallopian tube fimbriae and are
characterized by p53 signature mutations, typical of tubal
Fig. 1 a-d. High-grade serous
carcinoma of the right ovary in a
56-year-old BRCA1-mutation
carrier woman. Magnetic
resonance imaging (MRI) scan
with T2-weighted (a), post-
gadolinium fat-suppressed (FS)
T1-weighted (b) and diffusion-
weighted (c) images, showing a
complex cystic-solid
multilobulated right adnexal mass
with restricted diffusion on b600
image (c), with pathologically
proved capsule rupture, but
without metastases. Contrast-
enhanced computed tomography
(CECT) obtained 1 year later due
to a left supraclavicular palpable
painful mass confirms the
presence of a lymph node
metastasis (arrow in d)
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intraepithelial carcinomas. In addition, these studies failed to
identify reproducible precursor lesions in the ovaries [2, 12].
For these reasons, some experts consider ovarian and fallopian
tube cancer in BRCA-mutations carriers to be more properly
termed as adnexal carcinomas [19]. However, interpretation of
p53 signatures, defined as p53 positivity by immunohisto-
chemical staining in at least 12 secretory cells with a low
proliferative index, must be done cautiously, as it does not
mean a neoplastic lesion is present and is a quite common
occurrence in fallopian tubes, regardless of BRCA status [12].
Another cancer type, in whose progression the loss of
BRCA1 function with concurrent deletion of p53 may be an
important step, is uterine leiomyosarcoma, a rare
gynaecologic malignancies with a low survival rate [20].
As genetic testing for BRCA genes is not cost-effective for
the general population, thus far the selection of candidates still
relies on family history [1]. Once a genetic risk is confirmed,
management is not consensual, but usually includes serial
serum determinations of multiple tumour markers together
with transvaginal ultrasound, another option being prophylac-
tic oophorectomy after planned childbearing is completed.
Although a protective effect of oral contraceptives against
ovarian cancer is nearly proven, their routine prophylactic
use is no longer recommended due to the possible increased
relative risk of breast cancer in patients with HBOC syndrome
[5].
Lynch syndrome
Lynch syndrome (LS), caused by an autosomal-dominant he-
reditary germline mutation in one of the MMR genes—
MSH2, MLH1 and MSH6, in decreasing order [21]—predis-
poses to early onset of multiple cancer types, including colon,
endometrial and ovarian ones, sometimes with synchronous
presentation [22, 23]. MMR maintain genomic stability by
correcting mismatches generated during DNA replication,
their malfunction promoting cancer due to microsatellite in-
stability [24]. However, microsatellite instability is also
Fig. 2 a-d. Bilateral
undifferentiated ovarian
carcinomas in a 34-year-old
BRCA1-mutation carrier woman.
CT scan shows a large
multiloculated cystic left adnexal
mass with thick septa (a). A right
adnexal mass, similar to that one
described in image a, but with a
more prominent solid component,
was also present (b). Left para-
aortic lymph node metastases are
also present (c). Moderate ascites
is evident in all images but there
was no pleural effusion (d).
Pathologic examination ruled out
ovarian capsule and tubal
invasion
Fig. 3 Undifferentiated ovarian carcinoma in a 59-year-old BRCA2-
mutation carrier woman. CT scan demonstrates a large multilobulated
complex cystic-solid right adnexal mass. There were neither ascites nor
enlarged lymph nodes
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present in 15–20 % of corresponding sporadic cancers, usual-
ly due to MLH1 methylation [25].
Traditionally associated with colorectal cancer, it is nowa-
days consensual that women with LS are at equal or even
higher risk for development of gynaecologic malignancy
[26–29], as their sentinel cancer in more than half of cases
[30, 31]. Their lifetime cumulative risk of endometrial cancer
is 40–60 % [26, 28, 29, 31] and that of ovarian cancer is 10–
12% [18, 21, 27, 32–34], appearing to be particularly high for
MSH2-mutation carriers [35–37] and accounting for 2% of all
ovarian cancers [34].
Although it has long been thought that the average age of
onset of LS-related endometrial cancer is 45–50 years, in con-
trast to 65 years in sporadic cases [5, 38, 39], other studies
have suggested that a cutoff age of 50 years old for screening
could lead to 25–60 % of LS missing cases [40, 41], therefore
a cutoff age of 60 has already been advocated [22]. Regardless
of this controversy, a diagnosis of endometrial cancer at a
young age should raise suspicion for LS, especially if the most
typical constitutional factor of sporadic endometrial cancer—
obesity—is absent and family history is positive [42, 43].
Mean age for developing ovarian cancer is 40–48 years
among patients with LS [5, 36, 39].
While sporadic endometrial cancers that have microsatel-
lite instability are almost exclusively of endometrioid type,
usually well to moderately differentiated, those related to LS
tend to be histologically more diverse also occurring non-
endometrioid carcinomas, including serous, clear cell and un-
differentiated ones, although the majority is still of
endometrioid type [38, 43]. LS-related endometrial cancers
also show a predilection for the lower uterine segment, with
up to one-third of these tumours arising in this location
[44–46].
Although certain distinctive microscopic features of
endometrioid carcinomas, like poor differentiation, tumour
heterogeneity and increased tumour-infiltrating lymphocytes,
have been shown to be suggestive of the presence of high
levels of microsatellite instability [40, 47, 48], there are con-
flicting data regarding their utility [46].
Contrary to ovarian cancers of the general population or
that are HBOC syndrome-related, those related to LS are
mostly of the non-serous type, including endometrioid, clear
cell and undifferentiated carcinomas [36, 49]. Endometrioid is
most commonly associated with LS [36] and the second most
frequent histological subtype in the general population [50],
the majority being well to moderately differentiated and pur-
suing favourable clinical outcomes [36, 51]. There may be
synchronous endometrial thickening, representing either hy-
perplasia or carcinoma [52]. Among ovarian carcinomas as-
sociated with MMR defects, including LS-related ones, clear
cell subtype represents the majority [35].
Prognostic impact of MMR status is not clear for either
endometrial or ovarian carcinomas [12].
LS cases illustrated in Figs. 4 and 5 correspond to patients
whose sentinel cancers were gynaecologic, the latter with syn-
chronous endometrial and ovarian tumours.
Current gynaecologic cancer screening guidelines for
women with LS, which include annual endometrial
Fig. 4 a–d. Mixed serous-
endometrioid carcinoma of the
uterus in a 66-year-old woman
with Lynch syndrome.
Ultrasound (a) shows a solid
polypoid mass inside the uterine
cavity and a small hydrometra.
MRI scan demonstrates a solid
well-circumscribed endometrial
tumour, hypoenhancing
compared with myometrium on
post-gadolinium FS T1-weighted
image (b). Diffusion restriction on
the b1000 image (c) with a low
apparent diffusion coefficient
(ADC) value (d) is also evident,
consistent with its malignant
nature. The tumour was confined
to the corpus uteri with no
myometrial invasion
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sampling and transvaginal ultrasound beginning at 30–
35 years, are not considered to be effective, but are still
a reasonable option [12, 53].
Cowden syndrome
Cowden syndrome (CS), part of a broader category termed
PTEN hamartoma tumour syndrome, is characterized by a
mutation in the PTEN tumour-suppressor gene, which
leads to uncontrolled cell division and the formation
of hamartomatous neoplasms and certain cancers,
representing an increased lifetime risk of endometrial
carcinomas of 13–19 % [54].
Histologically, reported cases of CS-related endometrial
carcinomas [54–57] and the one illustrated in Fig. 6 are of
endometrioid type.
Although still not validated, the adoption of the screening
guidelines for LS, including annual endometrial biopsies be-
ginning at age 30 to 35, or 5 years before the earliest family
diagnosis of endometrial cancer and annual ultrasound exam-
ination with biopsy of suspicious areas for postmenopausal
women, has already been proposed [54]. Formal evaluation
for CS when endometrial cancer is diagnosed in adolescence
has also been suggested [55].
Li-fraumeni syndrome
Li-fraumeni syndrome (LFS) is an extremely rare autosomal-
dominant hereditary disorder characterized by a germline mu-
tation in the tumour-suppression gene p53, which leads to an
estimated 50-fold risk over the general population of develop-
ing several types of cancer [58], more than half occurring
before age 30 [59]. Although endometrial and ovarian cancers
have been found to occur excessively in at least some families
who have met criteria for LFS, their link to the syndrome is
not definitely established, occurring at a much lower rate than
other cancer types, like breast cancer [60].
Actually, the fact that distal fallopian tubes of women with
LFS are exquisitely prone to developing p53 signatures, iden-
tical to those described in BRCA1/2-mutations carriers and
general population, does not mean an association with ovarian
cancer, as at least one more genotoxic event is needed to
produce the malignant phenotype [61].
There are no studies specifically examining the relation
between LFS and endometrial cancer.
Fig. 5 a–d. Poorly differentiated endometrioid carcinomas of the left
ovary and of the endometrium in a 56-year-old woman with Lynch
syndrome. CECT shows a large complex cystic-solid multiloculated left
adnexal mass with no cleavage plane from the uterine corpus (a) in
concordance with invasion of the myometrium, as pathologically
demonstrated. The same image depicts the endometrial tumour, seen as
a polypoid solid lesion within the uterine cavity surrounded by fluid,
proved to be confined to the inner half of the endometrium. A CECT
scan obtained 2 months after hysterectomy with bilateral adnexectomy
without pelvic lymphadenectomy demonstrates in the sagittal plane (b)
a large pelvic mass arising from the vaginal cuff consistent with tumour
recurrence, as well as two abdominal wall implants (arrows). Left
hydronephrosis secondary to pelvic wall invasion (c) and a hepatic
subcapsular implant (d) are also evident in the same study
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Peutz-jeghers syndrome
Peutz-jeghers syndrome (PJS) is a rare autosomal domi-
nant disease due to mutations in the tumour-suppressor
gene STK11 [62], which predisposes not only to
hamartomatous gastrointestinal polyps and mucocutane-
ous pigmentation, but also to numerous malignancies, in-
cluding gynaecologic ones, the latter having a reported
relative risk of 27.7 % in comparison to the general pop-
ulation [63].
Risk of ovarian, cervical and uterine cancers associ-
ated with PJS is 18–21 %, 10 % and 9 %, respectively
[64].
PJS-related gynaecological cancers are of some character-
istic histological types, particularly the sex cord tumours with
annular tubules (SCTAT) of the ovary [63, 65–67], 36 % oc-
curring in association with this syndrome [65], although with
lower risk of malignant transformation than in the general
population [63]. This distinctive ovarian neoplasm, whose
predominant component has morphologic features intermedi-
ate between those of granulosa cell and Sertoli cell tumours,
may produce both oestrogen and progesterone [68]. This his-
tological type is followed by Sertoli cell, mucinous, serous
and mature teratoma [67].
There is also evidence that patients with PJS are prone to
develop endometrial adenocarcinomas [69, 70], especially
highly invasive ones [70].
Among cervical tumours, there is an important association
with minimal deviation adenocarcinoma [65, 66, 71], known
as adenomamalignum, with 10% of all cases occurring in PJS
patients [66]. This is a well-differentiated mucinous adenocar-
cinoma with highly aggressive behaviour, despite its decep-
tively benign appearance and very scarce cytological features
of malignancy within the tumour [71].
Gynaecologic cancer screening surveillance recommenda-
tions for patients with PJS include annual Papanicolaou test by
age 18 and annual pelvic examination and ultrasound by age
20 [72], which should also target the potential malignant
change of ovarian SCTAT [63].
Conclusions
Regardless of some genetic specifications, the following par-
ticularities concerning each of the syndromes discussed above
are consensual nowadays:
– HBOC syndrome is mainly associated with ovarian
HGSC, which seem to arise in the fallopian fimbriae
and have better prognosis than sporadic cancers.
– LS predisposes to endometrial cancer, at a lower rate than
ovarian cancers. Endometrial cancers show a predilection
for the lower uterine segment and tend to be histologically
more diverse in contrast to their sporadic counterparts,
including non-endometrioid carcinomas. Both LS and
CS-related ovarian cancers are mostly of non-serous type,
usually endometrioid.
– LFS only slightly increases the risk of endometrial and
ovarian cancers.
– PJS increases the risk of ovarian, cervical and uterine
cancers, in decreasing order, ovarian SCTAT and cervical
adenoma malignum being strongly associated.
– Unfortunately, hereditary gynaecologic cancers do not
seem to have any imaging characteristics that might be
reliably used to distinguish them from sporadic cancers.
– In order to ensure early identification of high-risk pa-
tients, every time a gynaecologic malignancy is diag-
nosed under the expected age in the general population,
a careful anamnesis including familial history of cancer
and genetic confirmation when indicated is required.
– Screening and surveillance schemes usually consist of an
annual pelvic examination with endometrial sampling
and ultrasound beginning in young adulthood.
Fig. 6 a, b. High-grade endometrioid carcinoma within an endometrial
hyperplastic polyp in a 62-year-old woman with Cowden syndrome. T2-
weighted image (a) shows distension of the uterine cavity due to a polyp,
more evident on post-gadolinium FS T1-weighted image (b), which is
hypoenhancing compared with myometrium. Normal uterine zonal
anatomy is preserved. Note the bosselated and smooth outer contour of
the uterus due to leiomyomas
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